WO2022011021A1 - Utilisation d'épitopes peptidiques conservés de sars-cov-2 pour le développement d'un vaccin à large spectre contre la covid-19 - Google Patents

Utilisation d'épitopes peptidiques conservés de sars-cov-2 pour le développement d'un vaccin à large spectre contre la covid-19 Download PDF

Info

Publication number
WO2022011021A1
WO2022011021A1 PCT/US2021/040700 US2021040700W WO2022011021A1 WO 2022011021 A1 WO2022011021 A1 WO 2022011021A1 US 2021040700 W US2021040700 W US 2021040700W WO 2022011021 A1 WO2022011021 A1 WO 2022011021A1
Authority
WO
WIPO (PCT)
Prior art keywords
cov
ecd
peptide
tremll
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2021/040700
Other languages
English (en)
Inventor
Yen-Ta Lu
Chia-Ming Chang
Ping-Yen Huang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ascendo Biotechnology Inc Taiwan
Lee Frank Wen-Chi
Original Assignee
Ascendo Biotechnology Inc Taiwan
Lee Frank Wen-Chi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascendo Biotechnology Inc Taiwan, Lee Frank Wen-Chi filed Critical Ascendo Biotechnology Inc Taiwan
Publication of WO2022011021A1 publication Critical patent/WO2022011021A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Definitions

  • Present invention relates to COVID-19 vaccines, and particularly to peptide-based vaccines comprising highly conserved epitopes from the spike protein of SARS-CoV-2.
  • SARS-CoV-2 became a significant global health problem, causing COVID-19 pandemic in March 2020. Because vaccines are the most economical means to control infectious diseases, broad and effective vaccines against SARS-CoV-2 infections are urgently needed.
  • SARS-CoV-2 is a positive-strand RNA virus that belongs to the group of beta-coronaviruses.
  • the genome of SARS-CoV-2 encodes 4 major structural proteins, including a spike (S) protein, an envelope (E) protein, a membrane (M) protein, and a nucleocapsid (N) protein.
  • SARS-CoV-2 enters host cells, primarily lung epithelial cells, through a catch-and-fuse process that involves interactions between its S protein and human angiotensin-converting enzyme 2 (ACE2) expressed on host cells.
  • ACE2 human angiotensin-converting enzyme 2
  • FIG. 1 shows a schematic illustrating a possible mechanism for SARS-CoV-2 entry into the host cells.
  • the spike (S) protein binds the ACE2 receptor on the host cells.
  • a protease transforms the spike protein.
  • the spike protein penetrates the host cells and brings the membrane of the host cell and the viral membrane closer. When the membranes fuse, it creates a pore for the viral genome to enter the host cells.
  • the spike protein S is cleaved into an N-terminal S 1 region and a C-terminal S2 region. These two sub-units mediate distinct tasks of attachment and entry into the host cells. Specifically, SI mediates the binding to ACE2 to allow the virus to attach to the host cells. On the other hand, S2 mediates fusion of viral and host cell membranes to create a pore for viral genome entry into the host cells. The S2 domain is further cleaved at the S2’ site to separate a fusion peptide (FP) from the internal fusion peptide, and the fusion peptide then participates in the viral entry process.
  • FP fusion peptide
  • the S protein or antibodies against the receptor-binding domain (RBD) contained in the S protein can serve as an immunogen to induce protective immunity. That is, antibodies against the S protein or antibodies against the receptor-binding domain (RBD) contained in the S protein may be able to prevent viral infections of the host cells.
  • the SARS-CoV-2 S 1 domain, which contains the RBD is frequently mutated, which can potentially make vaccines less effective or completely ineffective.
  • an important consideration in the vaccine design is to use a conserved antigen that can generate universal antibodies to prevent infection by SAR.S- CoV-2 variants.
  • Embodiments of the invention relate to the use of S2’ -peptides of SAR.S-CoV-2 as vaccine antigens or immune boosters. While the spike protein (S protein) of SAR.S-CoV-2 or the receptor-binding domain (RBD) in the spike protein of SAR.S-CoV-2 are popular targets for vaccine developments, inventors of the present invention have found that the S2’ -peptides, which surround the S2’ protease cleavage site, of SAR.S-CoV-2 provide more attractive targets.
  • the S2’ peptides are highly conserved among different coronavirus species, suggesting that these S2’ peptide sequences may play critical roles (e.g., membrane fusion and cell entry) for coronaviruses. Therefore, the S2’ peptides are less likely to have mutations in the ever-evolving variants of SAR.S-CoV-2.
  • Inventors of the invention have found that blocking the fusion domain of coronavirus using vaccines targeting the enzymatic S2’ -cleavage site can disrupt the virus entry processes, thereby neutralizing viral entry into the host cells.
  • inventors of the present invention have unexpected found that these S2’-peptides also can be used as agonist adjuvants, immune boosters, or carrier epitopes in vaccine developments.
  • a vaccine for generation of immunity against SAR.S-CoV-2 infection comprises an S2’ -peptide of SAR.S- CoV-2 in a formulation that enhances immune responses, wherein the S2’ -peptide comprises the amino acid sequence selected from SEQ ID NO: 1-10.
  • the formulation that enhances immune responses may comprise nanocomplexes encapsulating the S2’ -peptide, or the formulation includes TREM-like transcript- 1 (TREMLl) extracellular domain (ECD) or a stalk peptide as an immune booster.
  • the nanocomplexes may comprise poly- g-glutamic acid (g-PGA) and chitosan.
  • the TREM-like transcript-1 (TREMLl) extracellular domain (ECD) or stalk peptide may comprise the amino acid sequence selected from SEQ ID NO: 11-14.
  • a pharmaceutical composition for use in boosting an immune response comprises an S2’ -peptide of SARS-CoV- 2, wherein the S2’-peptide comprises the amino acid sequence selected from SEQ ID NO: 1-10.
  • FIG. 1 shows a schematic illustration of a catch-and-fuse process of coronavirus entry into host cells.
  • the spike (S) protein of the coronavirus binds the ACE2 receptor on the host cells.
  • a protease then transforms the spike protein, allowing the spike protein to penetrate the host cells and bring the membrane of the host cell and the viral membrane closer. After membrane fusion, a pore is formed to allow the viral genome to enter the host cells.
  • FIG. 2 shows a sequence alignment of S2’ cleavage sites between SARS-CoV, and SARS-CoV-2.
  • the fusion peptides and the protease cleavage sites are conserved between these viruses. These conserved sequences confer important functions in the host cell entry processes. While other parts of the viral genome are prone to mutations, these conserved fusion peptide sequences are unlikely to harbor any mutation, making them ideal as immunogens for vaccine development.
  • FIG. 3 shows a schedule of vaccinations, and blood samplings using a BALB/c mice model fortesting the immunogenicity of S2’ peptides.
  • NCs nanocomplexes
  • FIG. 4 shows serum antibody titers for the S2’ peptide-specific IgGl (serum dilution of 1:10000) and IgG2a (serum dilution of 1:1000) serum levels upon inoculations with S2’ peptide vaccines. Data are shown as S/N ratio.
  • FIG. 5 shows that the S2’-6/TREMLl ECD and S2’-l/NCs vaccines induce high titers of anti-spike (ECD) IgG antibodies in BALB/c mice. The results were presented as endpoint dilution serum titer.
  • FIG. 6 shows RBD-specific IgGl and IgG2a serum levels upon inoculations with RBD/TREMLl ECD vaccine or RBD/TREMLl ECD plus S2’-6/TREMLl ECD vaccine. Data are shown as S/N ratio at the final serum dilution of 1 : 10000.
  • FIG. 7 shows blocking effects of anti-sera from RBD/TREMLl ECD vaccine or RBD/TREMLl ECD plus S2’-6/TREMLl ECD vaccine on RBD-ACE2 bindings at the final serum dilution of 1 :2000. Data are shown as mean ⁇ SD. The dotted lines represent the cutoff at 20% inhibition.
  • FIG. 8 shows inhibitory effects of anti-sera from RBD/TREMLl ECD vaccine or RBD/TREMLl ECD plus S2’-6/TREMLl ECD vaccine on virus entry into host cells mediated by S-ACE2 interaction.
  • Embodiments of the invention relate to SARS-CoV-2 vaccines using the S2’ peptides derived from the spike protein of SARS-CoV-2.
  • These vaccines comprise S2’ peptides in unique nanocomplexes (NCs) that can elicit effective immune responses.
  • the S2’ peptides are formulated with the TREMLl extracellular domain (ECD) or stalk peptide as immune boosters.
  • ECD extracellular domain
  • TREMLl is triggering receptor expressed on myeloid cell-like transcript 1.
  • the S2’ peptides are important for viral entry into the host cells and the fusion peptides contained in the S2’ peptides are highly conserved among coronaviruses.
  • S2’ peptides ideal immunogens for designing SARS-CoV-2 vaccines.
  • embodiments of the invention also relate to the use of the S2’ peptides as agonist adjuvants or immune boosters in other vaccines.
  • Inventors of the invention found an electro-kinetic approach to preparing nanoparticle- based vaccine. This approach is quite different from the conventional vaccine technologies. This technique manipulates the electric double layers of solution systems to encapsulate proteins with (+/-)-charged polymers by compressive force to form a stable, narrow charge-distribution, and dispersive spherical nanocomplexes (cf. U.S. Patent No. 10,052,390 B2; ELI: 2754436; China: CN103910892B; Taiwan: 1511744; the disclosures of all these patents are incorporated by reference in their entirety).
  • Embodiments of the invention combine the nanoparticle-based approach with the SARS-CoV-2 S2’ peptide to achieve highly effective vaccines.
  • the S2’ peptides may be further formulated with a unique immune booster.
  • Inventors of the present invention have unexpectedly found that the extracellular domain (ECD) or its stalk of triggering receptor expressed on myeloid cell-like transcript 1 (TREMLl) can bind to TLR4/MD2 (LY-96, lymphocyte antigen 96).
  • TLR4/MD2 LY-96, lymphocyte antigen 96.
  • TREMLl ECD or its stalk can induce dendritic cell activation and maturation. Therefore, TREMLl ECD or its stalk can serve as vaccine adjuvants or immune boosters, as described in PCT/US2021/032620, filed on May 14, 2021, the disclosure of which is incorporated by reference in its entirety.
  • a conserved genome that rarely mutates is very likely associated with vital functions of a virus. Some of the conversed genomes may play a critical part in the strategies that viruses use to enter host cells, especially at the catch-and-fuse process.
  • the S2’ cleavage site is highly conserved between the SARS-CoV and SARS-CoV-2. Studies showed that monoclonal antibodies which recognized this cleavage site inhibited propagation of SARS- CoV in monkeys (The Journal of Infectious Diseases 203(11): 1574-81). We searched databases for the genetic variation of SARS-CoV-2 and determined several conserved S2’ sequences that have especially been mapped against the antibodies from those convalescent SARS patients.
  • S2’ peptide refers to a peptide derived from the sequence around the S2’ protease cleavage site in the spike protein of SARS-CoV-2, as illustrated in FIG. 2.
  • S2’-l to S2’- 10 peptides refer to specific sequences listed in Table I.
  • the abilities of these S2’ peptides to induce immune responses were investigated by examining their impacts on the production of antibodies.
  • Two different vaccine platforms were used. The first platform involves special nanocomplexes (NCs) to encapsulate the immunogens, and the second platform involves the use of a special immune response booster (i.e., TREMLl ECD or its stalk).
  • NCs nanocomplexes
  • TREMLl ECD TREMLl ECD or its stalk
  • immunogen peptides e.g., the S2’ peptides
  • the immunogen peptides are encapsulated in nanocomplexes using a simple electro-kinetic approach by addition of a charged polymer solution into another oppositely charged polymer solution.
  • the immunogen peptides were mixed with poly-y-glutamic acid (g-PGA) (M.W. preferably about 200 kDa or less, e.g., 10-200 kDa, 50-200 kDa, or 100-200 kDa) to form a first charged polymer solution.
  • g-PGA poly-y-glutamic acid
  • this solution was mixed with a second charged polymer solution (e.g., chitosan, CS) in an appropriate ratio.
  • a second charged polymer solution e.g., chitosan, CS
  • the molecular weight (MW) of chitosan is preferably about 10-100 kDa, adapted for adequate solubility at a pH value (e.g., pH value 5-9, preferably 6-8, more preferably 6.5-7.5) that maintains the bioactivity of protein and peptide drugs.
  • a pH value e.g., pH value 5-9, preferably 6-8, more preferably 6.5-7.5
  • the nanocomplexes preferably have zeta potentials of from about +30 mV to about +50 mV and a size range preferably from about 100 nm to about 800 nm.
  • These S2’ peptide/NCs are positively charged on the nanoparticle surfaces and are shown to have unusual abilities to induce immune responses, thereby having unusual therapeutic efficacies in the prevention and treatment of SARS-CoV-2 infections.
  • FIG. 3 shows a schematic illustrating a test protocol. Briefly, S2’ peptide/NCs at 10 pg per dose, or NCs alone as a control, were inoculated into BALB/c mice through subcutaneous (sc) or oral route at day 0, 14, and 28. The blood samples were obtained before vaccination and at day 42.
  • the above embodiments use nanocomplexes as a vaccine platform.
  • the nanocomplexes vaccines induce exceptionally robust immune responses.
  • some embodiments of the invention use a second platform.
  • the second vaccine platform involves the use of the extracellular domain (ECD) of TREM-like transcript- 1 (TREML1) protein.
  • TREML1 comprises an ECD (residues 1-162 or 16-162), a transmembrane domain (residues 163-183), and a cytoplasmic tail (residues 184-311).
  • the ECD of TREML1 comprises a single immunoglobulin variable (IgV) domain (residues 16-121) and a stalk (residues 122-162).
  • IgV immunoglobulin variable
  • the TREML1 ECD may be a mature ECD (residues 16-162) or a pro-ECD (residues 1-162, including the signal peptide), both of which will be generically referred to herein as TREML1 ECD.
  • Embodiments of the invention may use a TREML1 ECD or its stalk from human or another mammal (e.g., mouse).
  • Human TREML1 consists of 158 amino acids and has a molecular mass of 17.3 kDa.
  • TREML1 is exclusively found on platelets in the peripheral blood of humans. Upon platelet activation, TREML1 is quickly exposed on the membrane and subsequently cleaved, leading to the release of a soluble fragment (sTREMLl).
  • sTREMLl a soluble fragment
  • TREMLl ECD or its stalk can induce dendritic cell activation and maturation. Therefore, TREMLl ECD or its stalk can serve as vaccine adjuvants or immune boosters, as described in PCT/US2021/032620, filed on May 14, 2021, the disclosure of which is incorporated by reference in its entirety.
  • TREMLl ECD or TREMLl stalk peptides can function as immune boosters.
  • S2’ peptides may be mixed with recombinant or synthetic TREMLl ECD protein or a TREMLl stalk peptide in an appropriate ratio.
  • Examples of TREMLl ECD and stalk peptide sequences are shown in Table II. These vaccines may be referred to as TREMLl adjuvant vaccines in this description.
  • Each vaccine formulation may have an appropriate ratio of the S2’ peptide and the TREMLl ECD or stalk, e.g., 1-100 pg (preferably about 50 pg) S2’ peptide and 1-50 pg (preferably about 20 pg) recombinant or synthetic TREMLl ECD protein or stalk peptide in a typical vaccine dose.
  • Table II TREMLl ECD or Stalk Peptides used in exemplary embodiments of the invention.
  • mice were immunized subcutaneously (sc) with a TREMLl adjuvant vaccine (e.g., 50pg S2’ peptide and 20pg recombinant TREMLl ECD protein), and then booster vaccinations were administered subcutaneously using dosages similar to those for primary immunization on day 14 and day 28 post-primary immunization (as illustrated in FIG. 3).
  • TREMLl ECD alone was used as a control.
  • IgG2a titers were also significantly induced by the S2’-6/TREMLl ECD vaccine, but not by the TREMLl ECD alone. Similar results were observed in the mice treated with S2’-l/NCs vaccine. S2’-l/NCs induced both high titers of S2’-l-specific IgGl and IgG2a, whereas NCs alone did not. These results show that S2’ peptide vaccines of the invention have properties that can polarize T helper cells to induce both Thl and Th2 functions, suggesting that these vaccines can induce both cellular immune responses and humoral immune responses.
  • S2’ peptide vaccines can generate antibodies that can bind to the tertiary structure of the spike protein (i.e., the native structure of the spike protein).
  • SARS- CoV-2 spike extracellular domain ECD
  • FIG. 5 mouse sera from BALB/c mice after S2’-6/TREMLl ECD and S2’-l/NCs vaccinations were able to generate high titers of anti-SARS-CoV-2 spike (ECD) antibodies, while those vaccinated with TREML1 ECD alone or nanocomplexes alone did not.
  • S2’ peptide vaccinations not only can generate high titers of antibodies that can bind to primary structure of S2’ peptide but also can recognize tertiary structure of spike protein.
  • S2’ peptide vaccine can be used as an agonist adjuvant to induce strong neutralization antibody responses
  • TT peptide tetanus toxin peptide
  • PADRE pan HLA DR-binding epitope
  • S2’ peptide vaccine could strongly enhance anti-RBD antibody response when combine with RBD-based vaccine. This is probably due to the fact that S2’ peptide vaccines can polarize T helper cells to induce both Thl and Th2 functions, which then enhance the immune responses of the RBD/TREMLl ECD vaccine.
  • the antisera were also tested for their blocking effects against RBD-ACE2 binding.
  • mouse sera from BALB/c mice after RBD/TREMLl ECD vaccination generated antibodies that can block RBD-ACE2 interactions in vitro.
  • RBD/TREMLl ECD combined with S2’-6/TREMLl ECD vaccination generated substantially higher titers of blocking antibodies to inhibit RBD-ACE2 interactions.
  • the antisera were also tested for their neutralization capacity against SARS-CoV-2 infection using a pseudovirus neutralization assay.
  • the neutralization assays were performed by incubating pseudovirus with serial dilutions of serum, HEK-293T cells stably expressing human ACE2, and TMPRSS2 genes to see if the vaccinated mouse serum could protect cells from virus infections.
  • mouse sera from BALB/c mice after RBD/TREMLl ECD vaccination generated high titers of neutralizing antibodies and prevented pesudovirus infection in vitro.
  • RBD/TREMLl ECD Compared with RBD/TREMLl ECD vaccination, RBD/TREMLl ECD combined with S2’-6/TREMLl ECD vaccination generated higher titers of neutralizing antibodies to prevent pseudovirus infection.
  • S2’ peptide vaccine helps RBD-based vaccine to induce a significantly stronger neutralization antibody response.
  • S2’ peptides can also serve as agonist adjuvants or carrier epitopes suitable for use in the development of vaccines.
  • the antigen solution is prepared with 20 pg TREMLl ECD and various antigens (example: 20pg RBD or 50 pg S2’-6 peptide) in 50pl PBS.
  • Alhydrogel® adjuvant 2% InvivoGen, San Diego, CA, USA
  • the vaccine may be stored at room temperature.
  • mice All animal studies were conducted under specific pathogen-free conditions. In antibody induction experiments, six- to eight-week-old female BALB/c mice were divided into 2 groups: NC only and 10 pg/dose S2’-1/NC. Mice were inoculated with these vaccines at days 0, 14, and 28. The mouse blood samples were collected before vaccination and at day 42. In related studies, six- to eight-week-old male BALB/c mice were divided into 4 groups: TREML1 ECD only, 20 pg/dose RBD/TREMLl ECD, 50 pg/dose of S2’-6/TREMLl ECD, or 20 pg/dose RBD/TREMLl ECD + 50 pg/dose of S2’-6/TREMLl ECD. Mice were inoculated with these vaccines at days 0, 14, and 28. The mouse blood samples were collected before vaccination and at day 42.
  • Vaccines of the invention may be administered via any suitable routes, such as subcutaneous (sc), intravenous (iv), intramuscular (im), intraperitoneal (ip) injections, as well as via oral route or nasal route.
  • suitable routes such as subcutaneous (sc), intravenous (iv), intramuscular (im), intraperitoneal (ip) injections, as well as via oral route or nasal route.
  • Enzyme-linked immunosorbent assay for anti-S2’-l, anti-S2’-6, anti-RBD, and anti spike antibodies detection.
  • SARS-CoV-2 S2’-related peptide, RBD, or extracellular domain of spike (Spike ECD, GenScript) proteins are coated on 96-well plates at 5 ug/ml and kept at 4°C overnight.
  • Mouse sera are serially diluted and added into each well to incubate for 2 hours at room temperature.
  • Anti-mouse IgGl or anti-mouse IgG2a antibodies or anti-mouse IgG conjugated with HRP are added into wells and incubated for 30 min at room temperature. After wash, TMB substrate was added to produce color products, and the reactions were stopped by addition of IN HC1.
  • the optical density of each well was determined immediately, using a spectrophotometer set to 450 nm and 540 nm. The results are shown in FIG. 4-6.
  • Neutralization assays were performed by incubating pseudovirus with serial dilutions of heat inactivated serum, HEK-293T cells (1 c 10 4 ) stably expressing human ACE2 and TMPRSS2 genes in 50 pL of opti-MEM (Gibco) were seeded in each well of a black pCLEAR flat-bottom 96-well plate (Greiner Bio-oneTM). The cells were incubated overnight at 37°C with 5% CO2. On the following day, each serum was twofold serially diluted in opti-MEM and incubated with SARS-CoV-2 pseudotyped lentivirus at 37°C for 1 h.
  • the virus-serum mixture was transferred to the 293T/ACE2/TMPRSS2 cell plate with the final multiplicity of infection (MOI) of 0.1.
  • MOI multiplicity of infection
  • the culture medium was then replaced with fresh DMEM (supplemented with 10% FBS, 100 U/ml Penicillin/Streptomycin) at 16 hr post-infection, and cells were continuously cultured for another 56 hr. After incubating the infected cells at 37°C for 72 h, cells were quantified for GFP fluorescence on ImageXpress Micro Confocal High Content Imaging System (Molecular Devices).
  • the cells were stained with DAPI at 37°C for 20 min, and then GFP-positive cell and total cell nucleus were detected on ImageXpress Micro Confocal High Content Imaging System (Molecular Devices).
  • the raw images (5 x 5 sites, total 25 sites) were acquired using 20 c water immersion objective lens, processed, and stitched using the appropriate setting.
  • the total cells (indicated by nucleus staining) and GFP positive cells were quantified for each well. All analysis were carried out using MetaXpress Cell Scoring module, counting positive cell and total cell number at each site. After Cell Scoring analysis, the raw data was processed by Lumi-Vcal (LumiSTAR customized analysis software).
  • Transduction rates were determined by dividing the GFP-positive cell number with the total cell number. Relative transduction rates were obtained by normalizing the infection rates of serum treated groups to those of non-serum-treated controls. Inhibition percentage was obtained by considering the non-serum-treated control as 0% inhibition. The curves of the relative inhibition rates versus the serum dilutions were plotted using Prism 8 (GraphPad). A nonlinear regression method was used to determine the dilution fold at which 50% of GFP fluorescence (IC50) was expressed. Each serum was tested in triplicates. All SARS- CoV-2 pseudovirus neutralization assay was performed at the BSL-2 facility. Results are shown in FIG. 8.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Un vaccin permettant la génération d'une immunité contre une infection par le SARS-CoV-2 comprend un peptide S2' du SARS-CoV-2 dans une formulation qui améliore les réponses immunitaires, le peptide S2' comprenant la séquence d'acides aminés choisie parmi SEQ ID No : 1 à 10. La formulation comprend des nanocomplexes encapsulant le peptide S2', ou la formulation comprend le domaine extracellulaire du transcrit 1 de type TREM (TREML1) ou un peptide tige en tant qu'amplificateur immunitaire.
PCT/US2021/040700 2020-07-07 2021-07-07 Utilisation d'épitopes peptidiques conservés de sars-cov-2 pour le développement d'un vaccin à large spectre contre la covid-19 Ceased WO2022011021A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063048655P 2020-07-07 2020-07-07
US63/048,655 2020-07-07

Publications (1)

Publication Number Publication Date
WO2022011021A1 true WO2022011021A1 (fr) 2022-01-13

Family

ID=79552016

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/040700 Ceased WO2022011021A1 (fr) 2020-07-07 2021-07-07 Utilisation d'épitopes peptidiques conservés de sars-cov-2 pour le développement d'un vaccin à large spectre contre la covid-19

Country Status (2)

Country Link
TW (1) TW202208400A (fr)
WO (1) WO2022011021A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024038155A1 (fr) * 2022-08-17 2024-02-22 PMCR GmbH Immunisation contre une ou plusieurs infections virales
WO2024038157A1 (fr) * 2022-08-17 2024-02-22 PMCR GmbH Immunisation contre le coronavirus
LU103078B1 (en) * 2023-02-28 2024-08-28 PMCR GmbH IMMUNIZATION AGAINST CORONAVIRUS

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006071896A2 (fr) * 2004-12-23 2006-07-06 The Hong Kong University Of Science And Technology Vaccin contre le sras a base d'epitopes
US20120164174A1 (en) * 2009-06-25 2012-06-28 Bioleaders Corporation Adjuvant composition containing poly-gamma-glutamic acid-chitosan nanoparticles
US20170340725A1 (en) * 2015-10-22 2017-11-30 Modernatx, Inc. Combination piv3/hmpv rna vaccines
US20180141991A1 (en) * 2015-06-12 2018-05-24 Mackay Medical Foundation The Presbyterian Church In Taiwan Mackay Memorial Hospital Methods and polypeptides for modulation of immunoresponse
US20200061185A1 (en) * 2016-10-25 2020-02-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Prefusion coronavirus spike proteins and their use

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006071896A2 (fr) * 2004-12-23 2006-07-06 The Hong Kong University Of Science And Technology Vaccin contre le sras a base d'epitopes
US20120164174A1 (en) * 2009-06-25 2012-06-28 Bioleaders Corporation Adjuvant composition containing poly-gamma-glutamic acid-chitosan nanoparticles
US20180141991A1 (en) * 2015-06-12 2018-05-24 Mackay Medical Foundation The Presbyterian Church In Taiwan Mackay Memorial Hospital Methods and polypeptides for modulation of immunoresponse
US20170340725A1 (en) * 2015-10-22 2017-11-30 Modernatx, Inc. Combination piv3/hmpv rna vaccines
US20200061185A1 (en) * 2016-10-25 2020-02-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Prefusion coronavirus spike proteins and their use

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024038155A1 (fr) * 2022-08-17 2024-02-22 PMCR GmbH Immunisation contre une ou plusieurs infections virales
WO2024038157A1 (fr) * 2022-08-17 2024-02-22 PMCR GmbH Immunisation contre le coronavirus
LU103078B1 (en) * 2023-02-28 2024-08-28 PMCR GmbH IMMUNIZATION AGAINST CORONAVIRUS

Also Published As

Publication number Publication date
TW202208400A (zh) 2022-03-01

Similar Documents

Publication Publication Date Title
EP3156068B1 (fr) Compositions pharmaceutiques comprenant un polypeptide comprenant au moins un motif cxxc et des antigènes hétérologues et leurs utilisations
JP2003529319A (ja) ＨＩＶ−１ｇｐ４１を標的化する広範に中和する抗体を誘発する方法
WO2021203017A2 (fr) Vaccins nanocomplexes biodégradables, méthodes de prévention d'une infection par le coronavirus 2 responsable du syndrome respiratoire aigu sévère (sars-cov-2)
TW202208400A (zh) 來自ｓａｒｓ–ｃｏｖ–２之保守肽抗原決定基於開發廣泛型ｃｏｖｉｄ–１９疫苗之用途
Pan et al. Development of horse neutralizing immunoglobulin and immunoglobulin fragments against Junín virus
JP2025063151A (ja) 抗原性多量体呼吸器合胞体ウイルスポリペプチド
US20230398207A1 (en) Modulating th1/th2 immune response by administering two populations of polymersomes having an associated antigen and an associated adjuvant
US20230256082A1 (en) Vaccine against human-pathogenic coronaviruses
CA3100236A1 (fr) Vaccins a adn contre le coronavirus provoquant le syndrome respiratoire aigu severe
US20240366753A1 (en) Viral-like particles for the treatment or prevention of an infection by a coronaviridae virus
WO2012040266A2 (fr) Adjuvants de type gène et compositions les contenant pour augmenter la production d'anticorps en réponse à des vaccins géniques
TWI843471B (zh) 含抗原和dna之組成物及其用途
JP2001505763A (ja) Ｈｉｖ ｐ―１７ペプチドフラグメント、それを含有する組成物並びにその製造及び使用方法
US20240092840A1 (en) Vaccine formulation comprising recombinant overlapping peptides and native proteins
CA3157810A1 (fr) Vaccins contre les coronavirus
JP2025529904A (ja) Ｓａｒｓ－ｃｏｖ－２免疫原性組成物および方法
JP2023182231A (ja) Ｓａｒｓ－ｃｏｖ－２ ｓ糖タンパク質エクトドメインを含むプロテオリポソームおよびワクチンとしてのそれらの使用
CN121652268A (zh) 一种基孔肯雅病毒包膜e2蛋白单克隆抗体及其用途
HK1196952B (en) Liposomal formulations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21838160

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21838160

Country of ref document: EP

Kind code of ref document: A1